The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Bicara Therapeutics; Coherus Biosciences; Eisai; Labcorp Drug Development; Raptor Pharmaceuticals; Regeneron; Rgenta
Research Funding - Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Remix Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year
Travel, Accommodations, Expenses - Bicara Therapeutics
 
John Kaczmar
Stock and Other Ownership Interests - HCA Healthcare (I)
Honoraria - The Scienomics Group; Triangle Insights Group
Consulting or Advisory Role - Coherus Biosciences; EMD Serono/Merck; PDS Biotechnology; Rakuten Medical
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); ModeX Therapeutics (Inst); Novartis (Inst); Novocure (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Christine Chung
Consulting or Advisory Role - AVEO; Bicara Therapeutics; Exelixis; Fulgent Pharma; Genmab; Johnson & Johnson/Janssen; Regeneron; Seagen
Research Funding - Acrivon Therapeutics (Inst); Regeneron (Inst)
 
Dan Zandberg
Consulting or Advisory Role - Bicara Therapeutics; Blueprint Medicines; Coherus Biosciences; Coherus Biosciences; InhibRx; Macrogenics; Merck; Prelude Therapeutics; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); AVEO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Irene Brana
Consulting or Advisory Role - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim Spain; Cancer Expert Now; Gilead Sciences; Merck Sharp & Dohme; Merus
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD
Research Funding - AOP Health (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); Epizyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Hookipa Pharma (Inst); IDEAYA Biosciences (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); Tango Therapeutics (Inst); Tolremo (Inst); VCN Biosciences (Inst)
 
Caroline Even
Consulting or Advisory Role - Bristol-Myers Squibb; Fstar Therapeutics (Inst); GlaxoSmithKline (Inst); Innate Pharma; Merck Serono; Merus (Inst); MSD Oncology; Novartis (Inst)
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; MSD Oncology
 
Kevin Harrington
Honoraria - Abbvie (Inst); ALX Oncology (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicara Therapeutics (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Flamingo Pharma (Inst); GlaxoSmithKline (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); Merus (Inst); MSD (Inst); Nanobiotix (Inst); PDS Biotechnology (Inst); PsiVac Ltd (Inst); Replimune (Inst); Scenic Biotech
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)
 
Lisa Licitra
Honoraria - ALTIS Omnia Pharma Service Srl; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; Bicara Therapeutics; Boehringer Ingelheim; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Medscape LLC; Merck Healtcare KGaA; Merck Serono; MSD; MSD; Purple Biotech; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences
 
Bhumsuk Keam
Honoraria - AstraZeneca; Bayer; LG Chem; MSD Oncology; Yuhan
Consulting or Advisory Role - Handok; ImmuneOncia; TiumBio; Trial Informatics; Yuhan
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Danny Rischin
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Decibel Therapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Regeneron (Inst)
(OPTIONAL) Uncompensated Relationships - Eisai; GlaxoSmithKline; Merck; Regeneron
 
Rita Dalal
Employment - Bicara Therapeutics
 
David Raben
Employment - Bicara Therapeutics
 
Rachel Salazar
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics
Travel, Accommodations, Expenses - Bicara Therapeutics
 
Jeltje Schulten
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; Elevar Therapeutics; Grey Wolf Therapeutics; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; PDS Biotechnology; Remix Therapeutics; Replimune; Surface Oncology
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); Kura Oncology (Inst); Regeneron (Inst); Secura Bio (Inst)